Background

The effects of our patented treatment of the yeast, Saccharomyces cerevisiae, bioactive yeast cells with probiotic properties, have previously shown neuroprotective and neurorestorative properties on allergies. This was presented by a group of patients, who were compared with a matched group of patients that were given untreated yeast cells. Treated yeast cells were subjected to millimeter-wave exposure as described in patent documents. In addition to the patients in the study reporting clear improvements in their allergic symptoms, they also (self) assessed that their general health condition improved significantly. The patients assigned to untreated yeast cells did not report similar improvements.

The correlations between symptom improvement, general health and the number of weeks of treatment with Milmed mean that complete treatments are required for optimal therapeutic benefits. As previously observed, 10 to 14 weeks of treatment with ALNOZINE™ provides a distinct improvement in allergy symptoms and enhanced general health. For the past 13 years, research has been ongoing in Sweden with Professor Trevor Archer as head of research. Uppsala University, Linnaeus University in Kalmar and the University of Gothenburg have been important partners along the way. Since 2016, Milmed has also collaborated with the research university Sapenzia in Rome with Professor Rita Businaro as research leader.

Trevor has published nearly a thousand scientific articles during his long career and the most recent regarding Milmed in the Journal of Immunology and Allergy February 2020 and November 2020. This was after conducting an allergy study in 2018 with positive results on improvements for allergic disorders. Over 85% were fully recovered or markedly better. The study constituted the core for a patent application filed in 2019 which led to, in October 2020, The Company having an approved patent for treatment of allergic disorders. Allergic disorders are the largest disease group in the entire western world. (WAO). Since 2007 there has been 13 studies conducted and several studies are scheduled for 2021 and 2022. Among them a phase 1 study for the Company’s patent protected allergy product ALNOZINE™ in early 2022. In addition, the Sapienza team conducted an in vitro study that showed no toxicity in Milmed. Milmed nor Alnozine are harmful towards animals, plants or human beings.

Milmed unico

Download the Sapienza Report about toxicity

Full Report